Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Eikelboom, J. W.
Right arrow Articles by Hirsh, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Eikelboom, J. W.
Right arrow Articles by Hirsh, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Bleeding and management of bleeding

John W. Eikelboom1,* and Jack Hirsh2

1 Thrombosis Service, Hamilton General Hospital Hamilton Health Sciences Corporation and, McMaster University, 237 Barton Street, East Hamilton, Ontario L8L 2X2, Canada
2 Henderson Research Centre Hamilton Health Sciences Corporation and, McMaster University, 237 Barton Street, East Hamilton, Ontario L8L 2X2, Canada

* Corresponding author. Tel: +1 905 527 7327.E-mail address: eikelbj{at}mcmaster.ca

Clopidogrel is an effective antiplatelet drug for preventing cardiovascular events and death but also increases the risk of bleeding. There is emerging evidence that bleeding is associated with an increased risk of recurrent ischaemic events and death, even when the bleeding is not severe enough to be considered life-threatening. Reducing the risk of bleeding has the potential to improve clinical outcomes, but it is important to ensure that strategies aimed at reducing the risk of bleeding do not compromise the net clinical benefit of clopidogrel that has been demonstrated in clinical trials. Possible strategies to reduce the risk of bleeding during clopidogrel treatment include appropriate dosing of concomitant antithrombotic drugs and their avoidance unless they are of proven benefit, careful selection of patient for invasive procedures, and discontinuation of clopidogrel at least 5 days prior to coronary artery bypass graft surgery, except in unstable or very high risk patients. Management of bleeding in patients treated with clopidogrel may include temporary discontinuation of antithrombotic drugs, resuscitation with intravenous fluid, packed red cell transfusion, and surgical or other procedures to control the bleeding. The only way to overcome the antiplatelet effect of clopidogrel is with platelet transfusions because clopidogrel irreversibly inhibits platelet function for the life of the platelet, and there is no known antidote. Future research efforts should be directed towards establishing whether or not the association between bleeding and recurrent ischaemic events and death is causal and to determine the mechanism(s) responsible for the association.

Key Words: Clopidogrel • Bleeding • Myocardial infarction • Stroke • Death


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: II. Perioperative Considerations and Management
Anesth. Analg., August 1, 2008; 107(2): 570 - 590.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.